Labetalol HCl Injection Recalled for Manufacturing Cross-Contamination Risk
Nephron Sterile Compounding Center is recalling PF-Labetalol HCl Injection nationwide due to manufacturing deviations that create potential for cross-contamination. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall addresses potential manufacturing contamination in a sterile injectable product. Although no illnesses have been reported and the hazard remains theoretical, the risk posed by contamination in a sterile injectable medication warrants a High severity classification.
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling PF-Labetalol HCl Injection, USP, 20 mg/4 mL (5 mg/mL). The recall affects 33,870 vials (lot LB2005A, expiration date 3/2/2023) that were distributed nationwide.
The recall was issued due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. Specifically, there is potential for cross-contamination of the product due to carryover during the manufacturing process.
No illnesses or injuries have been reported in association with this recall.
The recalled product
- Product
- PF-Labetalol HCl Injection, USP, 20 mg/4 mL (5 mg/mL), One 4 mL Unit-Dose Vial, packaged in 30 x 4 mL Sterile Unit-dose Vials per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th Street Extension, West Columbia, SC 29172; NDC 69374-946-34
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug
- Hazard
- cross-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: LB2005A
- Exp 3/2/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01